Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.19
Views: 510

Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA

Dr Terry Mamounas speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the ten-year results from the NSABP B-42 trial.

He explains that this study aims to evaluate the effects of aromatase inhibitor therapy with letrozole in patients with postmenopausal, hormone receptor-positive breast cancer, that have completed five years of endocrine therapy.

Dr Mamounas provides an overview of the trial design and reports the findings from this ten-year update - where a trend was observed towards a benefit in disease-free survival.

He also discusses the possible reasons to explain why letrozole did not improve overall survival in this patient population.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation